eMedicine Specialties > Obstetrics and Gynecology > Labor and Delivery

Cervical Ripening

Author: Jodie Rai, MD, Clinical Associate Professor, Department of Obstetrics and Gynecology, Washington University School of Medicine; President, Women's Healthcare Consultants
Coauthor(s): James R Schreiber, MD, Professor, Department of Obstetrics and Gynecology, Washington University School of Medicine
Contributor Information and Disclosures

Updated: Aug 12, 2008

Introduction

In pregnancy, the uterine cervix serves 2 major functions. First, it maintains its firmness (ie, physical integrity) during pregnancy as the uterus dramatically enlarges. This physical integrity is critical so that the developing fetus can remain in the uterus until the appropriate time for delivery. Second, in preparation for labor and delivery, the cervix softens and becomes more distensible, a process called cervical ripening. These chemical and physical changes are required for cervical dilatation, labor, and delivery of a fetus.

See Medscape's Pregnancy Resource Center.

Uterine Characteristics

The human uterus is composed of 2 basic parts, the fundus and the cervix. The fundus is composed of myometrium, predominantly smooth muscle cells, and the endometrium. The endometrium undergoes dramatic changes during the menstrual cycle. In the absence of pregnancy, it sheds down to the basal layer at the end of the cycle. The normal pregnant cervix is 3.5 cm or longer and is composed predominantly of connective tissue, mainly collagen. In contrast to the fundus, it has only 10-15% smooth muscle. It changes little during the menstrual cycle and pregnancy until the onset of cervical ripening.

The human cervix consists mainly of extracellular connective tissue. The predominant molecules of this extracellular matrix are type 1 and type 3 collagen, with a small amount of type 4 collagen at the basement membrane. Intercalated among the collagen molecules are glycosaminoglycans and proteoglycans, predominantly dermatan sulfate, hyaluronic acid, and heparin sulfate. Fibronectin and elastin also run among the collagen fibers. The highest ratio of elastin to collagen is at the internal os. Both elastin and smooth muscle decrease from the internal to the external os of the cervix.

Role of Various Hormones in the Process of Cervical Ripening

A complex series of interactions occurs whereby various hormones stimulate the chemical reactions critical for cervical ripening. Associated with cervical ripening is an increase in the enzyme cyclooxygenase-2, which leads to a local increase of prostaglandin E2 (PGE2) in the cervix. The increase in local PGE2 leads to a series of important changes associated with cervical ripening, including the following:

  • Dilatation of small vessels in the cervix
  • Increase in collagen degradation
  • Increase in hyaluronic acid
  • Increase in chemotaxis for leukocytes, which causes increased collagen degradation
  • Increase in stimulation of interleukin (IL)–8 release

Prostaglandin F2-alpha is also involved in the process via its ability to stimulate an increase in glycosaminoglycans.

Cervical ripening is associated with increased activity of matrix metalloproteinases 2 and 9, enzymes that degrade extracellular matrix proteins. Cervical collagenase (also called matrix metalloproteinase 1) and elastase also increase. Near term, collagen turnover increases and degradation of newly synthesized collagen increases, which leads to decreased collagen content in the cervix.

In animal studies, sex steroids have been demonstrated to be involved in cervical ripening. In the rat cervix, increasing estrogen leads to increased collagenase activity, cervical cell apoptosis, and eosinophil infiltration. Animal models also exhibit a decrease in receptor-mediated progesterone activity, but whether this is involved in cervical ripening is unclear.

The role of inflammatory agents in cervical ripening has also been studied. IL-8 can lead to neutrophil chemotaxis, which is associated with collagenase activity and cervical ripening. These inflammatory agents may be particularly important as mediators of cervical ripening associated with preterm labor.

Recent study has focused on the nitric oxide synthase (NOS)/nitric oxide (NO) system. The NOS/NO system has been postulated to have a regulatory role in the myometrium and cervix during pregnancy and parturition. In rat studies, NO and increased NOS activity are associated with uterine quiescence. NOS activity is higher prior to labor and decreases during labor, thereby playing a role in the onset of uterine contractions associated with labor. In rat studies, NO levels and NOS activity behave in an opposite fashion in the cervix. Prior to cervical ripening, NOS activity is low and then increases at the time of labor, associated with cervical ripening. NOS activity leading to NO production is the final pathway in inducing chemical changes associated with cervical ripening. In the human cervix, ripening is associated with an increase in induced NOS (iNOS) and brain NOS expression in the cervix.

Resident and migrating inflammatory cells can cause the increase in iNOS activity. Indeed, in the primate, cervical ripening has many aspects of an inflammatory process—tissue remodeling and breakage of chemical bridges between collagen fibers. Inflammatory agents such as IL-1, tumor necrosis factor-alpha, and IL-8 seem to be involved in cervical ripening.

NO also appears to play a role in this process because animal studies show that increased cervical NO leads to an increase in metalloproteinase activity, cellular apoptosis in the cervix, and glycosaminoglycan synthesis in the cervix. All of these changes are associated with the cervical ripening process.

NO also could play a role in premature cervical ripening associated with preterm labor, particularly in preterm labor triggered by infection. Inflammatory cells are rich in iNOS activity, leading to a dramatic increase in NO in the cervix, which stimulates the chemical changes associated with cervical ripening and leads to preterm labor and delivery. Human and animal studies support a role for NO in the process of cervical ripening. NO donors, when applied to the cervix, induce cervical ripening.

To stop preterm labor successfully, both uterine contractions and cervical ripening must be halted. Speculating that this requires blockage of prostaglandin synthesis in the uterine fundus and cervix (and local NO synthesis in the cervix) is tempting. The role that inflammatory agents play in the cervical ripening process could explain the explosive nature of the cervical changes that occur in preterm labor, particularly when associated with uterine infections.

Evaluation of Cervical Ripening

A variety of techniques have been developed to quantify cervical ripening in order to predict the timing of labor and delivery. This quantification is useful for patients at risk for preterm labor and for helping predict which patients will respond to induction of labor for medical reasons or for postdate pregnancy.

The most commonly used methodology to evaluate cervical ripening is the Bishop score because it is simple and has the most predictive value. This score uses cervical dilatation, effacement, consistency, position, and the station of the presenting part. Other methods that have been described in the literature, generally for gauging the risk of preterm labor, include ultrasound assessment of the cervix and detection of fetal fibronectin in cervicovaginal secretions.

A Bishop score of 5 or more is considered significant for cervical ripening and favorable for induction of labor. Bishop score is calculated as follows:
  • Dilatation
    • For 0 cm, 0 points are scored.
    • For 1-2 cm, 1 point is scored.
    • For 3-4 cm, 2 points are scored.
    • For 5-6 cm, 3 points are scored.
  • Effacement
    • For 0-30%, 0 points are scored.
    • For 40-50%, 1 point is scored.
    • For 60-70%, 2 points are scored.
    • For 80%, 3 points are scored.
  • Station
    • For -3 station, 0 points are scored.
    • For -2 station, 1 point is scored.
    • For -1 and 0 station, 2 points are scored.
    • For +1 to +2 station, 3 points are scored.
  • Consistency
    • For firm consistency, 0 points are scored.
    • For medium consistency, 1 point is scored.
    • For soft consistency, 2 points are scored.
  • Position
    • For posterior position, 0 points are scored.
    • For mid position, 1 point is scored.
    • For anterior position, 2 points are scored.

Ultrasound assessment of the cervix helps measure the length of the cervix and helps determine the absence or presence of cervical funneling. A 2000 study by Cook and Ellwood (based on 120 at-risk women) demonstrated with linear regression analysis that prior to 20 weeks of pregnancy, a cervical length of less than 21 mm is highly predictive of preterm labor and delivery.1

Detection of fetal fibronectin in cervicovaginal secretions has also recently been used. Fetal fibronectin is a glycoprotein found in amniotic fluid and at the chorionic decidual interface. The absence of this protein in cervicovaginal secretions predicts prolongation of pregnancy. Fetal fibronectin is also predictive of response to prostaglandin application to the cervix at term in order to induce cervical ripening and labor.

Induction of Cervical Ripening

Bishop scores (see Bishop score) are somewhat subjective, but a score of less than 5 suggests further ripening is needed, while a score of 9 or greater suggests that ripening is completed. No maximum has been determined for the number of doses of a cervical ripening agent that can be given. Indeed, if the patient has no pressing indication for delivery and if fetal well-being parameters are reassuring, the patient can even be discharged, to return in a few days for another attempt at induction. Good clinical judgment is indispensable. A variety of methods have been developed to induce cervical ripening in the preparation of the cervix for labor and delivery.

Prostaglandins

Two forms of PGE2 (dinoprostone) are available commercially. In randomized trials, the 2 forms are equivalent in efficacy. The first is Prepidil, which is formulated as a gel and is placed inside the cervix, but not above the internal os. The application (3 g gel/0.5 mg dinoprostone) can be repeated in 6 hours, not to exceed 3 doses in 24 hours. The second is Cervidil, which contains 10 mg of dinoprostone embedded in a mesh and is placed in the posterior fornix of the vagina. This allows for controlled release of dinoprostone over 12 hours, after which it is removed.

Prostaglandin E1 analog (misoprostol) use was described recently in a series of articles. This is a synthetic prostaglandin, which is marketed as an antiulcer agent under the trade name Cytotec. One quarter of a tablet (25 mcg), which can be crushed and placed on the cervix, has been shown in several studies to be quite effective in inducing cervical ripening and labor. The application of the medication can be repeated every 4 hours.

Misoprostol has also been administered orally (50-100 mcg, which can be repeated every 4 h), but vaginal administration seems to be more efficacious. Vaginally administered misoprostol has been used for cervical ripening and labor induction in pregnancies complicated by oligohydramnios. In these patients, the risk for adverse perinatal outcomes was not increased compared with patients with normal amniotic fluid volumes. Note that the US Food and Drug Administration classifies Cytotec as a pregnancy category X drug. The manufacturer has been ambivalent about this off-label use of the medication, and the Food and Drug Administration only acknowledges that misoprostol is being used in pregnancy.

The American College of Obstetrics and Gynecology (ACOG) Committee on Obstetrics Practice recommends that misoprostol not be used in induction of labor after previous cesarean section or major uterine surgery, due to a significant risk of uterine rupture.2  

The major risk of the above prostaglandin preparations is uterine hyperstimulation. The woman and fetus must be monitored for contractions, fetal well-being, and changes in the cervical Bishop score. Finally, Christensen et al demonstrate that the combination of oxytocin induction, preceded by a dinoprostone insert is safe, and this significantly shortens induction-to-delivery times.3

The exception to this appears to be women with prior cesarean deliveries. The ACOG Committee on Obstetric Practice, in its review of pertinent literature, notes that the sequential use of prostaglandins and oxytocin appears to increase the risk of uterine rupture in women with previous cesarean section.

Low-dose oxytocin infusion

In this method, a low-dose oxytocin infusion is performed, with an increase in dose from 1 to 4 mU/min. Ferguson et al showed this method to be comparable to intravaginal misoprostol for cervical priming.4 Because of the ease of turning off the oxytocin infusion, they suggested that this method may have a preferential role in high-risk patients whose fetuses are at increased risk for intolerance of labor.

Antiprogesterone

Mifepristone (formerly known as RU 486) is a very effective antiprogesterone and antiglucocorticoid that works by binding to progesterone and glucocorticoid receptors. Randomized trials have shown it to be very effective in inducing labor.

Relaxin

Because of the results from a series of animal studies, relaxin has been predicted to have effects on cervical ripening in humans. The findings that porcine relaxin induces cervical ripening in humans supports this conclusion. Paradoxically, human relaxin has no effect on the human cervix, and relaxin is not currently used in cervical ripening or induction of labor. The reason for the species difference is unknown and calls into question the role of human relaxin in human parturition.

Balloon catheter

A 30- to 50-mL Foley catheter filled with saline is effective in inducing cervical ripening and dilatation. The catheter is placed in the uterus, and the balloon is filled. Direct pressure is then applied to the lower segment of the uterus and the cervix. This direct pressure causes stress in the lower uterine segment and probably the local production of prostaglandins. In some studies, the catheter is combined with a saline solution as an extra-amniotic infusion.5 There is no evidence that extra-amniotic saline infusion (EASI) increases the risk of chorioamnionitis.6 Prospective trials have shown that insertion of a Foley catheter is at least as effective as PGE2 gels, perhaps even more effective. This is particularly true in nulliparous women.

Hygroscopic dilators

Several products are available that can be placed in the cervix and dilated by water absorption. Laminaria are made from dried seaweed. Commercial products, Dilapan and Lamicel, are produced from synthetic hygroscopic material. Several dilators are inserted in the cervix—as many as will fit—and they expand over 12-24 hours as they absorb water. Absorption of water leads to expansion of the dilators and opening of the cervix. They probably work much the same as the balloon catheter. Women do not need prophylactic antibiotics for the balloon catheter or hygroscopic dilators, unless specific indications exist such as need for subacute bacterial endocarditis (SBE) prophylaxis.

Membrane stripping

Manual separation of the amniotic membranes from the cervix is thought to induce cervical ripening and the onset of labor. The mechanism is unknown, but mechanical disruption of this tissue has been postulated to cause an increase in local prostaglandins by the induction of phospholipase A2 in the cervical and membrane tissues. Such a postulation is certainly consistent with the known stimulation of cervical ripening by prostaglandins. However, there is no strong evidence at this time that membrane stripping significantly shortens the duration of pregnancy.

Nitric oxide donors

Studies are being conducted on the use of nitric oxide donors for cervical ripening. To this end, isosorbide mononitrate, 40 mg, and glyceryl trinitrate have been used in small studies with encouraging results.

Summary of induction of cervical ripening

Induction of cervical ripening is critical to successful induction of labor in a pregnant patient whose cervix has not gone through the ripening process. Cervical ripening allows the uterine contractions to effectively dilatate the cervix. The amount of uterine pressure to dilatate a ripe cervix is thought to be approximately 1600 mm Hg, while the pressure to dilatate an unripe cervix is estimated to be greater than 5 times that, or 10,000 mm Hg.

Economic Burden of Mistimed Cervical Ripening

Preterm labor and delivery

Accurate dating of pregnancy using early prenatal care and ultrasonography is advised before cervical ripening and induction of labor. Mistimed cervical ripening and induction can result in unplanned iatrogenic preterm birth. Current ACOG guidelines recommend against elective induction of labor, without medical indications, before 39 completed weeks of pregnancy.  Elective inductions account for about half of all inductions and 10% of deliveries.

In the United States, the national cost for preterm labor, undelivered, exceeds $360 million in total expenditures per year. Preterm labor hospitalization costs are in excess of $820 million. However, the direct economic cost is only a fraction of the ultimate cost of delivery of children who are preterm. The cost of immediate newborn care for preterm infants has been estimated at $5 billion annually, and long-term health costs are also very high.

Several studies have shown significant morbidity among children born prematurely. A 5-year follow-up evaluation of children born before 32 weeks' gestation showed significant language difficulties. Of children born weighing less than 1500 g, one fourth had severe or multiple psychological problems, with a significant decrease in intelligence quotient and school learning and an increase in discipline problems. A 10-year follow-up evaluation of children born before 29 weeks' gestation showed a significant increase in behavioral disorders in school and performance below grade level.

The great successes in neonatal nurseries and intensive care units have dramatically increased the ability of children who are significantly preterm to survive. However, the learning disabilities and behavioral disorders in this group are quite significant, creating an ongoing challenge for their parents, the schools, and society as a whole.

Economic and other consequences of postterm delivery

Postdate labor induction in a woman with an unripe cervix is also associated with difficulties. Labor is longer, more materials are used, and the rate of cesarean deliveries is higher. For example, the rate of cesarean deliveries in nulliparous women who are electively induced for postdate pregnancy is twice that of nulliparous women with the onset of spontaneous labor. The doubling of the rate leads to increased morbidity for the patient and increased cost to the health care delivery system. Therefore, whenever possible, cervical ripening is advised before induction in postdate pregnancies in which the cervix is unripe.

Contraindications to Cervical Ripening

Contraindications to cervical ripening include the following:

  • All contraindications to induction of labor and vaginal delivery, including the following:
    • Active herpes
    • Fetal malpresentation
    • Nonreassuring fetal well-being monitoring
    • A history of prior difficult or traumatic delivery
    • Regular contractions
    • Unexplained bleeding per vagina
    • Placenta previa
    • Vasa previa
  • Regular contractions
  • Maternal fever
  • A history of a prior cesarean section or major uterine surgery, because of the increased risk of uterine rupture
A relative contraindication to cervical ripening is ruptured membranes. At this time no evidence shows that cervical ripening followed by delayed induction of labor reduces the rate of cesarean section.7

Keywords

cervical ripening, cervix ripening, pregnancy, parturition, induced labor, labor inducement, premature birth, cervical dilatation, cervix dilatation, cervical dilation, cervix dilation, prematurity, premature infant, delivery, preterm delivery, normal pregnancy, vaginal delivery

 
Acknowledgments

We would like to thank Dr. Robert Kokenyesi for his assistance in reviewing the basic science portion of this review.



More on Cervical Ripening

References

References

  1. Cook CM, Ellwood DA. The cervix as a predictor of preterm delivery in 'at-risk' women. Ultrasound Obstet Gynecol. Feb 2000;15(2):109-13. [Medline].

  2. ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 342: induction of labor for vaginal birth after cesarean delivery. Obstet Gynecol. Aug 2006;108(2):465-8. [Medline].

  3. Christensen FC, Tehranifar M, Gonzalez JL, et al. Randomized trial of concurrent oxytocin with a sustained-release dinoprostone vaginal insert for labor induction at term. Am J Obstet Gynecol. Jan 2002;186(1):61-5. [Medline].

  4. Ferguson JE 2nd, Head BH, Frank FH, et al. Misoprostol versus low-dose oxytocin for cervical ripening: a prospective, randomized, double-masked trial. Am J Obstet Gynecol. Aug 2002;187(2):273-9; discussion 279-80. [Medline].

  5. Mullin PM, House M, Paul RH, Wing DA. A comparison of vaginally administered misoprostol with extra-amniotic saline solution infusion for cervical ripening and labor induction. Am J Obstet Gynecol. Oct 2002;187(4):847-52. [Medline].

  6. Karjane NW, Brock EL, Walsh SW. Induction of labor using a foley balloon, with and without extra-amniotic saline infusion. Obstet Gynecol. Feb 2006;107(2 Pt 1):234-9. [Medline].

  7. Mozurkewich E. Prelabor rupture of membranes at term: induction techniques. Clin Obstet Gynecol. Sep 2006;49(3):672-83. [Medline].

  8. Abramovici D, Goldwasser S, Mabie BC, et al. A randomized comparison of oral misoprostol versus Foley catheter and oxytocin for induction of labor at term. Am J Obstet Gynecol. Nov 1999;181(5 Pt 1):1108-12. [Medline].

  9. ACOG Committee on Obstetric Practice. Committee opinion. Induction of labor for vaginal birth after cesarean delivery. Obstet Gynecol. Apr 2002;99(4):679-80. [Medline].

  10. American College of Obstetricians and Gynecologists. ACOG Committee Opinion. Number 283, May 2003. New U.S. Food and Drug Administration labeling on Cytotec (misoprostol) use and pregnancy. Obstet Gynecol. May 2003;101(5 Pt 1):1049-50. [Medline].

  11. Bishop EH. Pelvis scoring for elective induction. Obstet Gynecol. Aug 1964;24:266-8. [Medline].

  12. Calder AA. Nitric oxide--another factor in cervical ripening. Hum Reprod. Feb 1998;13(2):250-1. [Medline].

  13. Chwalisz K, Garfield RE. Nitric oxide as the final metabolic mediator of cervical ripening. Hum Reprod. Feb 1998;13(2):245-8. [Medline].

  14. Dede FS, Haberal A, Dede H, et al. Misoprostol for cervical ripening and labor induction in pregnancies with oligohydramnios. Gynecol Obstet Invest. 2004;57(3):139-43. [Medline].

  15. Denison FC, Calder AA, Kelly RW. The action of prostaglandin E2 on the human cervix: stimulation of interleukin 8 and inhibition of secretory leukocyte protease inhibitor. Am J Obstet Gynecol. Mar 1999;180(3 Pt 1):614-20. [Medline].

  16. Friedman MA. Manufacturer's warning regarding unapproved uses of misoprostol. N Engl J Med. Jan 4 2001;344(1):61. [Medline].

  17. Goldberg AB, Greenberg MB, Darney PD. Misoprostol and pregnancy. N Engl J Med. Jan 4 2001;344(1):38-47. [Medline].

  18. Hale RW, Zinberg S. Use of misoprostol in pregnancy. N Engl J Med. Jan 4 2001;344(1):59-60. [Medline].

  19. Hughes EG, Kelly AJ, Kavanagh J. Dinoprostone vaginal insert for cervical ripening and labor induction: a meta-analysis. Obstet Gynecol. May 2001;97(5 Suppl 1):847-55. [Medline].

  20. Kashanian, M. Akbarian A. Baradaran H. Samiee MM. Effect of membrane sweeping at term pregnancy on duration of pregnancy and labor induction: a randomized trial. Gynecologic and Obstetric Investigation. 2006;62(1):41-44. [Medline].

  21. Kniss DA, Iams JD. Regulation of parturition update. Endocrine and paracrine effectors of term and preterm labor. Clin Perinatol. Dec 1998;25(4):819-36, v. [Medline].

  22. Leppert PC. Anatomy and physiology of cervical ripening. Clin Obstet Gynecol. Jun 1995;38(2):267-79. [Medline].

  23. Levey KA, MacKenzie AP, Stephenson C, et al. Increased rates of chorioamnionitis with extra-amniotic saline infusion method of labor induction. Obstet Gynecol. Apr 2004;103(4):724-8. [Medline].

  24. Luoma L, Herrgård E, Martikainen A, Ahonen T. Speech and language development of children born at < or = 32 weeks' gestation: a 5-year prospective follow-up study. Dev Med Child Neurol. Jun 1998;40(6):380-7. [Medline].

  25. Luque EH, Muñoz de Toro MM, Ramos JG, et al. Role of relaxin and estrogen in the control of eosinophilic invasion and collagen remodeling in rat cervical tissue at term. Biol Reprod. Oct 1998;59(4):795-800. [Medline].

  26. Lydon-Rochelle M, Holt VL, Easterling TR, Martin DP. Risk of uterine rupture during labor among women with a prior cesarean delivery. N Engl J Med. Jul 5 2001;345(1):3-8. [Medline].

  27. Moore, Lisa; Rayburn, William. Elective induction of labor. Clinical Obstetrics and Gynecology. September/2006;49(3):698-704. [Medline].

  28. Nicholson WK, Frick KD, Powe NR. Economic burden of hospitalizations for preterm labor in the United States. Obstet Gynecol. Jul 2000;96(1):95-101. [Medline].

  29. Nielsen PE, Howard BC, Hill CC, Larson PL, Holland RH, Smith PN. Comparison of elective induction of labor with favorable Bishop scores versus expectant management: a randomized clinical trial. J Matern Fetal Neonatal Med. Jul 2005;18(1):59-64. [Medline].

  30. Norman JE, Thomson AJ, Greer IA. Cervical ripening after nitric oxide. Hum Reprod. Feb 1998;13(2):251-2. [Medline].

  31. Nunes FP, Campos AP, Pedroso SR, Leite CF, Avillez TP, Rodrigues RD. Intravaginal glyceryl trinitrate and dinoprostone for cervical ripening and induction of labor. Am J Obstet Gynecol. Apr 2006;194(4):1022-6. [Medline].

  32. Osman I, MacKenzie F, Norrie J, Murray HM, Greer IA, Norman JE. The "PRIM" study: a randomized comparison of prostaglandin E2 gel with the nitric oxide donor isosorbide mononitrate for cervical ripening before the induction of labor at term. Am J Obstet Gynecol. Apr 2006;194(4):1012-21. [Medline].

  33. Poma PA. Cervical ripening. A review and recommendations for clinical practice. J Reprod Med. Aug 1999;44(8):657-68. [Medline].

  34. Riskin-Mashiah S, Wilkins I. Cervical ripening. Obstet Gynecol Clin North Am. Jun 1999;26(2):243-57. [Medline].

  35. Romero R. Clinical application of nitric oxide donors and blockers. Hum Reprod. Feb 1998;13(2):248-50. [Medline].

  36. Sanchez-Ramos L, Kaunitz AM, Delke I, Gaudier FL. Cervical ripening and labor induction with a controlled-release dinoprostone vaginal insert: a meta-analysis. Obstet Gynecol. Nov 1999;94(5 Pt 2):878-83. [Medline].

  37. Sciscione AC, McCullough H, Manley JS, et al. A prospective, randomized comparison of Foley catheter insertion versus intracervical prostaglandin E2 gel for preinduction cervical ripening. Am J Obstet Gynecol. Jan 1999;180(1 Pt 1):55-60. [Medline].

  38. Shetty A, Livingstone I, Acharya S, et al. Oral misoprostol (100 microg) versus vaginal misoprostol (25 microg) in term labor induction: a randomized comparison. Acta Obstet Gynecol Scand. Dec 2003;82(12):1103-6. [Medline].

  39. Stenlund PM, Ekman G, Aedo AR, Bygdeman M. Induction of labor with mifepristone--a randomized, double-blind study versus placebo. Acta Obstet Gynecol Scand. Oct 1999;78(9):793-8. [Medline].

  40. Stjernholm YM, Sahlin L, Eriksson HA, et al. Cervical ripening after treatment with prostaglandin E2 or antiprogestin (RU486). Possible mechanisms in relation to gonadal steroids. Eur J Obstet Gynecol Reprod Biol. May 1999;84(1):83-8. [Medline].

  41. Stjernqvist K, Svenningsen NW. Ten-year follow-up of children born before 29 gestational weeks: health, cognitive development, behaviour and school achievement. Acta Paediatr. May 1999;88(5):557-62. [Medline].

  42. Stygar D, Wang H, Vladic YS, et al. Increased level of matrix metalloproteinases 2 and 9 in the ripening process of the human cervix. Biol Reprod. Sep 2002;67(3):889-94. [Medline].

  43. Tam WH, Tai SM, Rogers MS. Prediction of cervical response to prostaglandin E2 using fetal fibronectin. Acta Obstet Gynecol Scand. Nov 1999;78(10):861-5. [Medline].

  44. Tschugguel W, Schneeberger C, Lass H, et al. Human cervical ripening is associated with an increase in cervical inducible nitric oxide synthase expression. Biol Reprod. Jun 1999;60(6):1367-72. [Medline].

  45. Upadhyaya NB, Childs KD, Neiger R, Caudle MR. Ambulatory cervical ripening in term pregnancy. J Reprod Med. Apr 1999;44(4):363-6. [Medline].

  46. Weeks A, Alfirevic Z. Oral misoprostol administration for labor induction. Clin Obstet Gynecol. Sep 2006;49(3):658-71. [Medline].

  47. Wieland D, Friedman F Jr. Comparing two dinoprostone agents for preinduction cervical ripening at term. A randomized trial. J Reprod Med. Aug 1999;44(8):724-8. [Medline].

  48. Wolke D. Psychological development of prematurely born children. Arch Dis Child. Jun 1998;78(6):567-70. [Medline].

  49. Yeast JD, Jones A, Poskin M. Induction of labor and the relationship to cesarean delivery: A review of 7001 consecutive inductions. Am J Obstet Gynecol. Mar 1999;180(3 Pt 1):628-33. [Medline].

Further Reading

Keywords

cervical ripening, cervix ripening, pregnancy, parturition, induced labor, labor inducement, premature birth, cervical dilatation, cervix dilatation, cervical dilation, cervix dilation, prematurity, premature infant, delivery, preterm delivery, normal pregnancy, vaginal delivery

Contributor Information and Disclosures

Author

Jodie Rai, MD, Clinical Associate Professor, Department of Obstetrics and Gynecology, Washington University School of Medicine; President, Women's Healthcare Consultants
Jodie Rai, MD is a member of the following medical societies: Alpha Omega Alpha, American Association of Gynecologic Laparoscopists, American College of Obstetricians and Gynecologists, American Medical Association, and Association of Professors of Gynecology and Obstetrics
Disclosure: Cervimark LLC Ownership interest Management position

Coauthor(s)

James R Schreiber, MD, Professor, Department of Obstetrics and Gynecology, Washington University School of Medicine
James R Schreiber, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Obstetricians and Gynecologists, and Society for Gynecologic Investigation
Disclosure: Nothing to disclose.

Medical Editor

Robert K Zurawin, MD, Associate Professor, Director of Baylor College of Medicine Program for Minimally Invasive Gynecology, Director of Fellowship Program, Minimally Invasive Surgery, Department of Obstetrics and Gynecology, Baylor College of Medicine
Robert K Zurawin, MD is a member of the following medical societies: American Association of Gynecologic Laparoscopists, American College of Obstetricians and Gynecologists, American Society for Reproductive Medicine, Association of Professors of Gynecology and Obstetrics, Central Association of Obstetricians and Gynecologists, Harris County Medical Society, North American Society for Pediatric and Adolescent Gynecology, and Texas Medical Association
Disclosure: Johnson and Johnson Honoraria Speaking and teaching; Conceptus Honoraria Speaking and teaching

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Richard S Legro, MD, Professor, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology, Pennsylvania State University College of Medicine; Consulting Staff, Milton S Hershey Medical Center
Richard S Legro, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Society for Reproductive Medicine, Endocrine Society, Phi Beta Kappa, and Society of Reproductive Surgeons
Disclosure: Nothing to disclose.

CME Editor

Frederick B Gaupp, MD, Consulting Staff, Department of Family Practice, Hancock Medical Center
Frederick B Gaupp, MD is a member of the following medical societies: American Academy of Family Physicians
Disclosure: Nothing to disclose.

Chief Editor

Carl V Smith, MD, The Distinguished Chris J and Marie A Olson Chair of Obstetrics and Gynecology, Professor, Department of Obstetrics and Gynecology, University of Nebraska Medical Center
Carl V Smith, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Institute of Ultrasound in Medicine, American Medical Association, Arkansas Medical Society, Association of Professors of Gynecology and Obstetrics, Central Association of Obstetricians and Gynecologists, Council of University Chairs of Obstetrics and Gynecology, Nebraska Medical Association, and Society for Maternal-Fetal Medicine
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.